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A 69-year-old woman with underlying diabetes mellitus and
chronic hepatitis B suffered frommultiple indurated erythematous
plaques on the trunk and extremities for 3 years (Figure 1A and B).
The plaques, initially noted on the bilateral thigh with progression
to trunk and upper arms, were asymptomatic. She had also lost
weight during the past year. Physical examination revealed
enlarged lymph nodes at the bilateral axillae. We obtained a skin
biopsy from the thigh. The histopathological examination showed
mild atrophic epidermis with focal epidermotropism and dense
inﬁltrate of small- to medium-sized atypical lymphocytes in the
dermis (Figure 2AeD). Nodular pattern inﬁltration with granulo-
matous reaction and multinucleated giant cells were found in the
dermis (Figure 2B). No caseous necrosis or foreign body was noted
in the granuloma area. Acid-fast stain, periodic acideSchiff stain,
and GrocotteGomori methenamine silver stain showed negative
ﬁndings. Immunohistochemical studies revealed that atypical
small- to medium-sized lymphocytes expressed CD3þ and CD4þ
(Figure 2E) with CD7 loss. The atypical lymphocytes did not express
CD8, CD20, or CD30. The diagnosis of CD4-positive granulomatous
mycosis fungoides (GMF) was made on the basis of clinical and his-
tological ﬁndings.
Laboratory examination revealed anemia (hemoglobin, 10.6 g/
dL), thrombocytopenia (platelets, 120  1012/L), and normal white
blood cell counts (4.7  109/L). Elevated blood lactate dehydroge-
nase level (303 U/L) was also noted. Human T-lymphotrophicFigure 1 Multiple asymptomatic erythematous indurated plaques over (A) trunk and (B) p
follow-up photograph showed improvement of leg lesions.
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mocytic erythrocytes, normochromic white blood cells, and
adequate platelets. Bone marrow study reported no abnormal
lymphoid cell inﬁltration. The whole-body computed tomography
showedmultiple enlarged axillary, mediastinal, and inguinal lymph
nodes without extralymphatic organ involvement. Positron emis-
sion scanning also showed hypermetabolic nodes in bilateral
thighs, bilateral inguinal, bilateral iliac, and bilateral axillary areas.
Ill-deﬁned areas with increased ﬂourodeoxyglucose uptake in the
soft tissue of bilateral lower legs and left upper arm were also
seen. The ﬁnal diagnosis wasMF T2N1M0 Stage IIA. Although no tu-
mor was found clinically, because the histopathology revealed
tumor-like deeper inﬁltration rather than plaque-type MF, the
oncologist suggested treating this case aggressively as stage IIB
(T3N1M0) disease.
She was diagnosed in August 2011 and received one course of
chemotherapy with the ProMACE regimen. She next received oral
psoralen plus ultraviolet A therapy at the out-patient department
with improvement (Figure 1C). However, chest computed tomogra-
phy revealed newly found multiple nodules of lung involvement in
July 2013. Chemotherapy (ProMACEeCytoBOM) was resumed in
August 2013.
GMF is a rare histological variant of mycosis fungoides (MF),
characterized by a granulomatous inﬁltrate pattern. The ﬁrst
description of this variant was reported by Ackerman and Flaxman
in 1970. However, the clinical features of GMF have no distinct dif-
ference from classic MF. Patients often present with typical steppedroximal limbs with ﬁne scales. (C) After chemotherapy and PUVA therapy, the 1-year
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Figure 2 (A) At scanning magniﬁcation, there was dense inﬁltration of tumor cells in
the dermis (hematoxylin and eosin; original magniﬁcation: 40). (B) Granulomatous
pattern with multinucleated giant cells were seen at higher magniﬁcation (hematoxy-
lin and eosin; original magniﬁcation: 200). (C) Atypical lymphocytes were shown in
high-power view with arrows (hematoxylin and eosin; original magniﬁcation: 400).
(D) Epidermotropism of tumor cells were seen in focal area (hematoxylin and eosin;
original magniﬁcation: 200). (E) Tumor cells with epidermotropism were CD4 posi-
tive (immunohistochemistry stain; original magniﬁcation: 200).
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tion has also been reported.1
The diagnosis of GMF can be challenging, because its granulo-
matous inﬂammation pattern can be mistaken for other types of
granulomatous dermatitis. Sarcoid granuloma patterns are most
often found, and granuloma annulare patterns and tuberculoid-
like granuloma have also been reported.2,3 Other causes of infec-
tious and noninfectious granulomatous disease must be ruled
out. CD4-positive GMF is most common, although rare cases of
CD8-positive GMF have been reported.4 Atypical lymphocytes, epi-
dermotropism, Pautrier microabscesses, and dermal ﬁbrosis are
common histological ﬁndings of classic MF.5 These ﬁndings are
also typical features for GMF, but epidermotropism has been found
in approximately half of reported GMF cases.6 Atypical lymphocyte
inﬁltration and clinical correlation are important for differential
diagnosis. T-cell receptor gene clonal rearrangement detection
may be helpful for diagnosis. However, MF in its granulomatous
form can still be difﬁcult to diagnose. A previous study found thatthe average duration before diagnosis of GMF was longer than for
classic MF (8.4 years vs. 4.3 years, respectively).7
The granulomatous inﬁltrate pattern has not been found to be a
conclusive positive prognostic marker. Initially, a granulomatous
reaction was thought to be an immune response reaction and a
sign of a better prognosis. However, a caseecontrol study7 reported
more frequent disease progression in granulomatous MF than in
classic MF (46% and 30%, respectively). Compared with classic MF,
the progression-free rate of GMF was signiﬁcantly lower at 5-year
(84% of classic MF vs. 56% of GMF) and 10-year follow-up (59% of
classic MF vs. 33% of GMF).7 However, no signiﬁcant difference
was found in overall survival. Poorer response to skin-directed
therapy was observed in GMF patients versus classic MF patients,
and more aggressive treatment may be required for the former.8
Our patient received one cycle of ProMACE chemotherapy, followed
by PUVA therapy. Disease progression with multiple lung nodule
involvement was noted 23 months later.
In summary, we present a case of GMF, which is rarely reported
in Taiwan. Dermatologists should be alert to the possibility of
mistaking GMF for other types of granulomatous inﬂammation
inﬁltrate disease. The prognosis of GMF is controversial, and more
study is needed.
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